Try our Advanced Search for more refined results

Boehringer Must Show How IP 'Thicket' Blocked Humira Rival

By Tiffany Hu ( February 25, 2019, 5:39 PM EST) -- Boehringer Ingelheim must hand over its launch plans for a biosimilar version of AbbVie Inc.'s hugely popular immunosuppressant Humira, a Delaware magistrate judge has ruled in a patent infringement case, finding the information is relevant to Boehringer's defense that AbbVie created an illegitimate, anti-competitive "thicket" of duplicative and unoriginal patents....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Attached Documents

Related Sections

Case Information

Case Title

Subscribers Only

Case Number

Subscribers Only

Court

Subscribers Only

Nature of Suit

Subscribers Only

Judge

Subscribers Only

Date Filed

Subscribers Only

Law Firms

Companies

Government Agencies

Patents

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!